Opus Genetics shares were up 22% at $1.21, after the company said it saw positive topline results from a pivotal Phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the ...

The phase 3 trial observed the treatment of chronic night driving impairment in keratorefractive patients with reduced ...